Contact Customer Service or Scientific Support
Download our Catalog
Subscribe to eNewsletters
Archived Webinar – Watch on Demand:
CRISPR/Cas9 Cell Therapeutics – The Next
Generation of Cures
Register to watch
Browse our databases for further information on:
Transfection of physiologically relevant primary cells or stem cells is typically a very difficult task using traditional transfection methods. Additionally, when using relevant cell lines as model systems, the critical issues are to achieve reproducibly efficient transfection with high levels of viability while matching throughput capability required at each project phase – from proof of concept, through to scale-up and screening-like approaches.
With the electroporation-based Nucleofector™ Technology primary cells and stem cells, as well as cell lines, can be consistently transfected at high efficiency. Developed in 1998, Nucleofection™ has evolved through continuous innovation into a comprehensive portfolio of devices and kits for many different transfection needs.
Transfection Publications with Amaxa™ Nucleofector™ Technology
More than 6000 papers for hard-to-transfect cells
Nucleofector™ Technology Publications (cumulative numbers)
Download our list of selected Nucleofector™ Publications focusing on immunology, neurobiology, reprogramming and genome editing.